Size: | Price | Quantity | |
---|---|---|---|
5 mg | $70.00 | ||
25 mg | $250.00 |
SNS-314 mesylate (1146618-41-8) is a potent and selective pan-Aurora kinase inhibitor (IC50’s: Aurora A = 9 nM, Aurora B = 31 nM, Aurora C = 3 nM).1,2 It was able to inhibit proliferation in a wide panel of human cancer cell lines including colon (HCT116), breast (MDA-MB-231), prostate (PC-3), lung (H1299, Calu-6), ovarian (A2780), melanoma (A375) and liver (SMMC-7721, HepG2, LM6).1-4
References/Citations:
1) Oslob et al. (2008) Discovery of a potent and selective aurora kinase inhibitor; Bioorg. Med. Chem. Lett. 18 4880
2) Arbitrario et al. (2010) SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo; Cancer Chemother. Pharmacol. 65 707
3) VanderPorten et al. (2009) The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model; Mol. Cancer Ther. 8 930
4) Liu et al. (2017) Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma; Oncotarget 8 27953
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
SNS-314 mesylate (1146618-41-8) is a potent and selective pan-Aurora kinase inhibitor (IC50’s: Aurora A = 9 nM, Aurora B = 31 nM, Aurora C = 3 nM).1,2 It was able to inhibit proliferation in a wide panel of human cancer cell lines including colon (HCT116), breast (MDA-MB-231), prostate (PC-3), lung (H1299, Calu-6), ovarian (A2780), melanoma (A375) and liver (SMMC-7721, HepG2, LM6).1-4
References/Citations:
1) Oslob et al. (2008) Discovery of a potent and selective aurora kinase inhibitor; Bioorg. Med. Chem. Lett. 18 4880
2) Arbitrario et al. (2010) SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo; Cancer Chemother. Pharmacol. 65 707
3) VanderPorten et al. (2009) The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model; Mol. Cancer Ther. 8 930
4) Liu et al. (2017) Targeting high Aurora kinases expression as an innovative therapy for hepatocellular carcinoma; Oncotarget 8 27953
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.